Stabilized external preparation comprising thymosin beta 4 as an active ingredient
US11179443B2 · kind B2 · utility
0Cited by
2References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 4, 2017 |
| Grant date | Nov 23, 2021 |
| Priority date | — |
| Expiry date | Aug 4, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a stabilized external preparation comprising thymosin beta 4 (Tβ4) as an active ingredient. More specifically, the present invention relates to a therapeutically effective external preparation with improved stability and biological activity of Tβ4. The preparation according to the present invention provides Tβ4 in a stable state by maintaining the biological activity of Tβ4 and minimizing the generation of Tβ4 sulfoxide through oxidization reactions and multimers through aggregation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.